A ‘mix and match’ approach to #SARS-CoV-2 #vaccination | Nature Medicine
▻https://www.nature.com/articles/s41591-021-01463-x
Although triggered by the unfortunate interruption in the use of adenovirus-based vaccines, cross-platform mixed-dosing strategies have demonstrated advantageous immunogenicity outcomes, as measured by both humoral responses and cellular responses to the original SARS-CoV-2 and its #variants. These innovative vaccine-dosing schedules may be required both as proof against vaccine supply interruptions and for maximizing immune responses, which in turn will help to reduce the transmission of emerging variants and protect immunocompromised people.